Navigation Links
TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment

LOD, Israel--(BUSINESS WIRE)--Jul 9, 2007 - TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today promising results of its phase I clinical trials demonstrating the safety and pharmacokinetic profile of its ViaDerm-hPTH (1-34) product for the treatment of osteoporosis.

A seven day, repeated dose application, parallel group study was conducted on 48 healthy, elderly, post-menopausal women. The study was designed to evaluate the safety and tolerability of ascending multiple doses of hPTH (1-34) patches and to compare the pharmacokinetic profiles of the transdermally delivered doses of hPTH (1-34) with that of FORTEO(R) administered subcutaneously.

Transdermal hPTH (1-34) was delivered using TransPharma's fully integrated product, which is comprised of a proprietary pocket-sized device and 1 cm(2) dry hPTH (1-34) patch with demonstrated room-temperature stability.

Once-daily transdermal delivery of all doses tested in this trial demonstrated a safety profile similar to the one observed in the FORTEO(R) subcutaneous injection. All safety parameters (including calcium and phosphorous) of the different transdermal doses were within the normal range. Furthermore, all ViaDerm-hPTH (1-34) doses were very well tolerated by participants.

Pharmacokinetic profiles of hPTH (1-34) in the first and seventh day were similar, showing no accumulation of hPTH (1-34) levels and no deterioration in hPTH (1-34) systemic levels. These findings demonstrate the ViaDerm-hPTH (1-34) product's ability to provide reproducible drug levels resulting in excellent inter- and intra-participant variability.

Transdermally delivered hPTH (1-34) of all doses showed desirable peak profiles with relative bioavailability of approximately 40%. This bioavailability is amo
'"/>




Page: 1 2 3

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
7. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
8. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
9. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
10. Limiting Eligibility for Medical Studies Can Omit Women, African-Americans, Stanford Study Finds
11. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
Post Your Comments:
(Date:9/17/2014)... YORK , Sept. 17, 2014 ... Summary GlobalData,s new report, "Germany Gynecological ... data on the Germany Gynecological Devices market. The ... volume (in units) and average prices (in US ... (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization Devices ...
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 ... of PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") ... Robert S. Willoughby at rswilloughby@pomlaw.com or ... PDL BioPharma and certain of its officers and/or directors ... Exchange Act of 1934.  On September ...
(Date:9/17/2014)... Sept. 17, 2014 Bronstein, Gewirtz & Grossman, ... of the securities of PDL BioPharma, Inc. ("PDL BioPharma" ... Such investors are advised to contact Peretz Bronstein ... at info@bgandg.com or 212-697-6484. ... of its executives violated federal securities laws. ...
Breaking Medicine Technology:Germany Gynecological Devices Market Outlook to 2020 2Germany Gynecological Devices Market Outlook to 2020 3SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
... Annual Review of the Pharmaceutical Industry and the issues it ... Analyst Christopher Bowe. Bowe,s articles top issues faced by the ... Management" – an examination of how companies will use lifecycle ... corporate value , "Stamp Your Mark and Lead" – ...
... Edwards, Inc. (Nasdaq: MSHL ), an oncology ... targeting cancer metabolism, announced today that it has filed ... and Exchange Commission for a rights offering to existing ... common stock. The Company will announce further details regarding ...
Cached Medicine Technology:Need for Pharma Industry Change, Effective Lifecycle Management and Corporate Brand Reputation Featured in Scrip 100 2Marshall Edwards Announces Rights Offering to Stockholders 2Marshall Edwards Announces Rights Offering to Stockholders 3
(Date:9/18/2014)... 18, 2014 INDIGO Biosciences, a leading ... that it has released a new Human Estrogen-related Orphan ... kits are available. , ERR? is naturally expressed in ... in a variety of other tissue types, including kidney, ... a potential target for anti-obesity therapeutics. Cross-talk between ...
(Date:9/18/2014)... September 18, 2014 Sutter Health’s California ... founder of Dolby Laboratories, by naming the Ray Dolby ... of Ray Dolby provided a founding gift of $21 ... which provides services to patients and families suffering from ... people have been treated at the center since its ...
(Date:9/18/2014)... September 18, 2014 Dentists from ... of highly acclaimed Oxnard All-on-4™ dental implants ... a prosthodontist from the Anacapa Dental Art Institute ... the Canadian Academy of Restorative Dentistry and Prosthodontics ... Reshad’s presentation, “Resection Versus Augmentation: Esthetic Implant Supported ...
(Date:9/18/2014)... 2014 Each year, Norman Regional Hospital ... coincide with National Health IT (NHIT) Week to celebrate ... help Norman Regional show its gratitude, Access, the ... is contributing giveaway items to support their NHIT Week ... and offering free lunches, Norman Regional is spending time ...
(Date:9/18/2014)... Fla (PRWEB) September 18, 2014 According to ... suffer from eczema, with many of them being children. In ... first diagnosed as babies and children. The millions of children ... can be brought on by eczema. A new book has ... who they are and to find relief from the condition ...
Breaking Medicine News(10 mins):Health News:INDIGO Offers Human Estrogen-related Receptor Gamma Assay System 2Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 2Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 3Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 2Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 3Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 4Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 5Health News:Access Helps Norman Regional Hospital Celebrate Its Staff During National Health IT Week 2014 2Health News:New Book Helps Millions of Children Deal With The Emotional Pains of Suffering From Eczema 2
... these conditions go untreated , , MONDAY, May 12 (HealthDay News) ... are bad for your heart, they may also harm your ... to increase one,s risk for retinal vein occlusion, a condition ... more veins carrying blood from the eye to the heart ...
... PITTSBURGH Carnegie Mellon Universitys Justin Y. Newberg and Robert F. Murphy have ... protein patterns in human tissues., ... student in biomedical engineering, described the automated protein pattern recognition tool and ... for cancer diagnosis and therapy. , ...
... Damir Matic, a scientist with Lawson Health Research Institute in ... performed throughout North America and around the world. Matic ... close the gum tissue of cleft palate patients. His research ... is older. , Matic is a craniofacial/plastic surgeon at London ...
... U.S. survey estimates 750,000, mostly males, are hooked , , ... American teens and young adults are problem gamblers according ... on Addictions. , Problem gambling is defined as ... as gambling more than you intended or stealing money ...
... OmniSonics Medical,Technologies, Inc., a developer of advanced medical ... announced today that it has enrolled its,first patient ... a prospective,multi-center U.S. registry study of the company,s ... thrombectomy,for acute limb ischemia (ALI). All patients enrolled ...
... BETHESDA, Md., May 12 Naturlose, a natural sugar,approved as ... found to,reduce the spikes of serum glucose that follow consumption ... (Nasdaq: SPEX ) is currently,studying the efficacy and safety ... trial is ongoing, Spherix has engaged market,research companies to seek ...
Cached Medicine News:Health News:High Blood Pressure, Cholesterol Associated With Eye Disease 2Health News:Carnegie Mellon engineering researchers automate analysis of protein patterns 2Health News:Research shows timing improves cleft palate surgery 2Health News:Problem Gambling Common Among Young Adults 2Health News:OmniSonics Medical Technologies Announces First Patient Enrolled in SONIC II REGISTRY 2Health News:Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients 2Health News:Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: